PriceTargets.com logo

Merus - MRUS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $42.78
  • Forecasted Upside: 97.13%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$21.70 As of 06/2/2023 12:14 PM ET
▼ -0.79 (-3.51%)

This chart shows the closing price for MRUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRUS

Analyst Price Target is $42.78
▲ +97.13% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $42.78, with a high forecast of $49.00 and a low forecast of $33.00. The average price target represents a 97.13% upside from the last price of $21.70.

This chart shows the closing price for MRUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Merus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2023CitigroupBoost Target$47.00 ➝ $48.00Low
5/5/2023HC WainwrightBoost Target$40.00 ➝ $48.00Low
4/18/2023Stifel NicolausBoost TargetBuy$34.00 ➝ $44.00Low
4/18/2023BMO Capital MarketsBoost Target$47.00 ➝ $49.00Low
4/17/2023SVB SecuritiesBoost TargetOutperform$35.00 ➝ $48.00Low
4/17/2023GuggenheimBoost TargetBuy$38.00 ➝ $45.00Low
4/17/2023CitigroupBoost TargetBuy$38.00 ➝ $47.00Low
4/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$35.00Low
4/14/2023Needham & Company LLCReiterated RatingBuy$33.00Low
4/6/2023Needham & Company LLCReiterated RatingBuy$33.00N/A
4/5/2023CitigroupBoost TargetBuy$30.00 ➝ $38.00Low
3/16/2023BMO Capital MarketsBoost TargetOutperform$46.00 ➝ $47.00Low
3/1/2023Needham & Company LLCLower TargetBuy$35.00 ➝ $33.00Low
3/1/2023EF Hutton Acquisition Co. IReiterated RatingBuy$35.00Low
3/1/2023HC WainwrightBoost TargetBuy$39.00 ➝ $40.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$35.00Low
11/16/2022CitigroupLower TargetBuy$34.00 ➝ $30.00Low
11/4/2022SVB LeerinkLower TargetOutperform$39.00 ➝ $35.00Low
11/4/2022Needham & Company LLCLower TargetBuy$40.00 ➝ $28.00Low
11/4/2022HC WainwrightLower TargetBuy$45.00 ➝ $39.00N/A
10/13/2022SVB LeerinkBoost TargetOutperform$33.00 ➝ $39.00Low
8/17/2022CitigroupLower TargetBuy$37.00 ➝ $34.00Low
8/2/2022Stifel NicolausInitiated CoverageBuy$38.00Low
7/18/2022GuggenheimBoost TargetBuy$44.00 ➝ $46.00Low
5/19/2022CitigroupLower TargetBuy$38.00 ➝ $37.00Low
5/10/2022HC WainwrightReiterated RatingBuyMedium
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$45.00Low
2/10/2022Needham & Company LLCInitiated CoverageBuy$45.00Low
11/12/2021HC WainwrightBoost TargetBuy$30.00 ➝ $45.00Medium
11/3/2021Royal Bank of CanadaBoost TargetSector Perform$21.00 ➝ $33.00High
10/11/2021CitigroupBoost TargetBuy$31.00 ➝ $38.00Medium
10/8/2021SVB LeerinkBoost TargetOutperform$33.00 ➝ $45.00Low
10/7/2021Roth CapitalBoost TargetBuy$32.00 ➝ $40.00High
8/9/2021HC WainwrightReiterated RatingBuy$30.00High
6/11/2021William BlairReiterated RatingBuyLow
6/7/2021CitigroupUpgradeNeutral ➝ BuyHigh
5/9/2021SVB LeerinkReiterated RatingBuy$33.00High
4/8/2021William BlairInitiated CoverageOutperformMedium
3/17/2021Royal Bank of CanadaBoost TargetSector Perform$15.00 ➝ $21.00Low
3/17/2021HC WainwrightBoost TargetBuy$23.00 ➝ $30.00Medium
3/16/2021SVB LeerinkInitiated CoverageOutperform$33.00High
1/19/2021Roth CapitalBoost Target$19.00 ➝ $32.00High
8/7/2020HC WainwrightReiterated RatingBuy$23.00High
7/14/2020HC WainwrightReiterated RatingBuy$23.00High
6/26/2020HC WainwrightInitiated CoverageBuy$23.00High
5/27/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$21.00 ➝ $16.00High
5/18/2020GuggenheimLower TargetBuy$26.00 ➝ $23.00High
5/13/2020Royal Bank of CanadaReiterated RatingBuy$21.00Low
11/20/2019GuggenheimInitiated CoverageBuy$25.00Medium
6/28/2019Roth CapitalInitiated CoverageBuy ➝ Buy$20.00High
4/12/2019GuggenheimInitiated CoverageBuy$25.00High
4/5/2019WedbushLower TargetOutperform ➝ Outperform$34.00 ➝ $25.00Low
4/3/2019Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$18.00 ➝ $23.00High
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$35.00High
3/21/2019CitigroupLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00Medium
3/15/2019CitigroupLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00Low
7/27/2018WedbushReiterated RatingOutperform ➝ Outperform$26.00 ➝ $34.00Low
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
Mentions as of
11/4/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 5 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/3/2023
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Merus logo
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $21.70
Low: $21.66
High: $22.67

50 Day Range

MA: $20.09
Low: $17.40
High: $23.94

52 Week Range

Now: $21.70
Low: $12.03
High: $30.81

Volume

36,966 shs

Average Volume

364,925 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Merus?

The following Wall Street analysts have issued research reports on Merus in the last twelve months: BMO Capital Markets, Citigroup Inc., EF Hutton Acquisition Co. I, Guggenheim, HC Wainwright, Needham & Company LLC, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and SVB Securities.
View the latest analyst ratings for MRUS.

What is the current price target for Merus?

9 Wall Street analysts have set twelve-month price targets for Merus in the last year. Their average twelve-month price target is $42.78, suggesting a possible upside of 97.1%. BMO Capital Markets has the highest price target set, predicting MRUS will reach $49.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $33.00 for Merus in the next year.
View the latest price targets for MRUS.

What is the current consensus analyst rating for Merus?

Merus currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRUS will outperform the market and that investors should add to their positions of Merus.
View the latest ratings for MRUS.

What other companies compete with Merus?

Other companies that are similar to Merus include OPKO Health, Avadel Pharmaceuticals, Mirum Pharmaceuticals, Deciphera Pharmaceuticals and Day One Biopharmaceuticals. Learn More about companies similar to Merus.

How do I contact Merus' investor relations team?

Merus' physical mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company's listed phone number is (130) 253-8800 and its investor relations email address is [email protected]. The official website for Merus is www.merus.nl. Learn More about contacing Merus investor relations.